Max Lataillade

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 253 citations

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

Judith A. Aberg, Gilles Pialoux, Pedro Cahn et al. · New England Journal of Medicine · 2020 · 169 citations · Full text

Multidrug-resistant Hiv-1 Infection, Antiretroviral Drugs, Human Retrovirus +14

Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance

Max Lataillade, Jennifer Chiarella, Michael J. Kozal · Antiviral Therapy · 2007 · 146 citations · Full text

<i>In Vitro</i>Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

Beata Nowicka-Sans, Yi-Fei Gong, Brian McAuliffe et al. · Antimicrobial Agents and Chemotherapy · 2012 · 137 citations · Full text

Prodrug Bms-663068, Hiv-1 Gp120, Medicine +13

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

Max Lataillade, Jennifer Chiarella, Rong Yang et al. · PLoS ONE · 2010 · 130 citations · Full text